Brigette Roberts, M.D.

Brigette Roberts, M.D. is the Chief Executive Officer and a Director of OrphAI Therapeutics. Dr. Roberts joined OrphAI Therapeutics after serving as an Entrepreneur in Residence at Fortress Biotech. Prior to this, she spent over fifteen years in healthcare investing as a portfolio manager at hedge funds including Third Point, CDP Capital, Angel Lane Principal Strategies, DKR Capital and her own hedge fund, YYC Capital, which landed her on the Fortune “40 under 40: Ones to Watch” list. Over her investment career, she conducted activist work in several biotechnology companies, including Ligand Pharmaceuticals where she served as a Board Member. Dr. Roberts holds an M.D. degree from NYU and a B.A. degree in Physics and Chemistry from Harvard.